Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 125 versus STALEVO 150.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 125 versus STALEVO 150.
STALEVO 125 vs STALEVO 150
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 125 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life of levodopa.
Stalevo 150 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its bioavailability. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa.
One tablet of STALEVO 125 (levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg) orally, one tablet per dose, up to maximum 10 tablets per day. Frequency: typically every 4-6 hours while awake, adjusted based on response.
One tablet orally three times daily. Each tablet contains 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone.
None Documented
None Documented
Levodopa: 1-3 hours (short half-life necessitates frequent dosing with carbidopa to reduce peripheral metabolism). Carbidopa: 1-2 hours (not clinically significant alone). Entacapone: 0.4-0.7 hours (short half-life; acts primarily during absorption phase of levodopa).
Levodopa (with carbidopa): ~1.5-2 hours. Carbidopa: ~1-2 hours. Entacapone: ~0.4-0.7 hours (short half-life; not primary determinant of dosing interval). Clinically, levodopa half-life determines dosing frequency for motor fluctuations.
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) accounts for >70% of dose; <1% unchanged. Carbidopa: renal excretion of unchanged drug (~30%) and metabolites (~70%). Entacapone: primarily fecal excretion (~90%) with ~10% renal; entacapone glucuronide and unchanged drug in urine.
Carbidopa and levodopa are primarily excreted renally. Levodopa: ~70-80% renal, with metabolites including 3-O-methyldopa. Carbidopa: ~50-70% renal, with ~30% fecal. Entacapone: ~90% fecal (mainly as metabolites), ~10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent